A Phase II Trial of Erlotinib and Radiotherapy in Patients With Stage III Cutaneous Squamous Cell Carcinomas.

Trial Profile

A Phase II Trial of Erlotinib and Radiotherapy in Patients With Stage III Cutaneous Squamous Cell Carcinomas.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Skin cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RAD0503
  • Most Recent Events

    • 18 Oct 2011 Planned End Date changed from 1 Dec 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.
    • 26 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 06 Jun 2008 The expected completion date for this trial is now 1 Dec 2011, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top